Mair, Colette
,
Wulaningsih, Wahyu
Jeyam, Anita
McGurnaghan, Stuart
Blackbourn, Luke
Kennon, Brian
Leese, Graham
Lindsay, Robert
McCrimmon, Rory J.
McKnight, John
Petrie, John R.
Sattar, Naveed
Wild, Sarah H.
Conway, Nicholas
Craigie, Ian
Robertson, Kenneth
Bath, Louise
McKeigue, Paul M.
Colhoun, Helen M. http://orcid.org/0000-0002-8345-3288
Funding for this research was provided by:
Diabetes UK (17/0005627)
Chief Scientist Office (ETM/47)
Article History
Received: 18 December 2018
Accepted: 12 April 2019
First Online: 18 May 2019
Duality of interest
: HMC has received grants, personal fees and non-financial support from Eli Lilly & Company, grants from Pfizer Inc., grants from Boehringer Ingelheim, grants from AstraZeneca LP, grants, personal fees and non-financial support from Sanofi, non-financial support from Novartis Pharmaceuticals and personal fees and non-financial support from Regeneron. HMC received grants from and holds shares at Roche Pharmaceuticals, is a shareholder in Bayer and has received non-financial support from Sanofi Aventis outside the submitted work. All other authors declare that there is no duality of interested associated with their contribution to this manuscript.